Clinical trialNo phase (not a drug trial)Completed
EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial
- Outcome
- Finished, no results posted
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- 20 December 2018
- Ended
- 16 August 2021
- Enrollment
- 38 participants
- Sites
- 2
- Primary outcomes
- Change in tumour size as measured on EUS and or CT; Change in serum levels of Ca 19-9
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 30 August 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.
Detailed description public domain (ClinicalTrials.gov)
The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ablation (RFA) has been developed in our unit and used in patients with unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis .